Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BAUSCH HEALTH COMPANIES INC.

(BHC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Bausch Health : REFILE-UPDATE 1-Drugmaker Bausch to sell stake in Egypt's Amoun Pharma for $740 mln

03/31/2021 | 08:59am EDT

March 31 (Reuters) - Canadian drugmaker Bausch Health Companies Inc said on Wednesday it would sell all its stake in Egypt's Amoun Pharmaceutical Co SAE to Abu Dhabi-based ADQ for about $740 million, as the company looks to reduce its debt.

Bausch has been shedding non-core assets to pay down debt and last year announced plans to spin off its eye care unit Bausch + Lomb into a separate company. https://reut.rs/3m8kbvd

Valeant had purchased Amoun for about $800 million in 2015 to expand into the Middle East and North African pharmaceuticals market.

Goldman Sachs & Co LLC and Morgan Stanley & Co LLC served as financial advisors to Bausch for the transaction.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Rashmi Aich)


ę Reuters 2021
All news about BAUSCH HEALTH COMPANIES INC.
06/08BAUSCH HEALTHá : ANNOUNCES EARLY TENDER RESULTS AND EARLY SETTLEMENT DATE FOR CA..
PU
06/08BAUSCH HEALTH COMPANIES INC.á : Entry into a Material Definitive Agreement, Crea..
AQ
06/08BAUSCH HEALTHá : + Lomb, Lochan to Develop Next-Generation of Clinical Decision ..
MT
06/08BAUSCH HEALTH BRIEF : Bausch + Lomb and Lochan Enter Into Agreement to Develop t..
MT
06/03BAUSCH HEALTHá : And Clearside Biomedical Announce U.S. FDA Filing Acceptance Fo..
AQ
06/03BAUSCH HEALTHá : + lomb and clearside biomedical announce u.s. fda filing accept..
AQ
06/02BAUSCH HEALTHá : And Clearside Biomedical Announce U.S. FDA Filing Acceptance Fo..
MT
06/02BAUSCH HEALTHá : Clearside Biomedical's Resubmission of Xipere Application Accep..
MT
06/02BAUSCH HEALTH BRIEF : Bausch Health And Clearside Biomedical Announce U.S. FDA F..
MT
06/01BAUSCH HEALTHá : + Lomb and Prevent Blindness Launch Educational Campaign During..
AQ
More news
Financials (USD)
Sales 2021 8 611 M - -
Net income 2021 -719 M - -
Net Debt 2021 21 594 M - -
P/E ratio 2021 -16,4x
Yield 2021 -
Capitalization 11 300 M 11 300 M -
EV / Sales 2021 3,82x
EV / Sales 2022 3,50x
Nbr of Employees 21 600
Free-Float 95,6%
Chart BAUSCH HEALTH COMPANIES INC.
Duration : Period :
Bausch Health Companies Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAUSCH HEALTH COMPANIES INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 34,88 $
Last Close Price 31,53 $
Spread / Highest target 74,4%
Spread / Average Target 10,6%
Spread / Lowest Target -36,6%
EPS Revisions
Managers and Directors
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Thomas J. Appio President & Co-Head-Bausch Lomb International
Sam Eldessouky CFO, Chief Accounting Officer, SVP & Controller
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BAUSCH HEALTH COMPANIES INC.51.59%11 300
JOHNSON & JOHNSON5.08%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.7.66%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.70%203 857